d2 cont'd

diagram of AdRSVpHyde was illustrated in Fig. 1. The sequence of AdRSVpHyde is set forth in Figure 10 (SEQ ID NO: 5 and SEQ ID NO: 6).--

Please replace the paragraph beginning on page 77, line 32 with the following rewritten paragraph:

d3.

--**Characterization of cDNA**: *Sequencing-p-Hyde* cDNA was originally obtained as a λZAP Uni XR clone, and was further subcloned into pBluescript SK vector through *in vivo* excision protocol as described (Stratagen, La Jolla, California). This double-stranded cDNA was further subjected for Dye Terminator Cycle Sequencing (Perkin Elmer, Foster City, California) using ABI 377 automatic DNA sequencer Version 3.0. The open reading frame of *p-Hyde* cDNA was determined using the DNA Strider program (Pasteur Institute, Paris). --

In the Claims:

Please amend the following claims to read as follows:

d4

1. (Amended) An isolated nucleic acid molecule which encodes a mammalian p-Hyde protein, including variants, analogs and mutants thereof, said nucleic acid molecule set forth in SEQ ID No. 1.

d5

7. (Amended) The isolated nucleic acid molecule of claim 1, wherein the nucleic acid is DNA, c-DNA or RNA.

d6

10. (Amended) The isolated nucleic acid molecule of claim 1, wherein the nucleic acid is labeled with a detectable marker.

11. (Amended) The isolated nucleic acid molecule of claim 10, wherein the detectable marker is a radioactive, colorimetric, luminescent, fluorescent or gold label.

12. (Amended) An oligonucleotide of at least 15 nucleotides capable of specifically hybridizing with the molecule of claim 1.

d7

17. (Amended) An antisense molecule capable of specifically hybridizing with the isolated nucleic acid molecule of claim 1.

18. (Amended) A vector comprising the isolated nucleic acid molecule of claim 1.

d7 Cont'd

19. (Amended) The vector of claim 18, further comprising an regulatory element linked to the nucleic acid molecule.

20. (Amended) The vector of claim 18, wherein the regulatory element comprises a bacterial, yeast, insect or mammalian promoter.

21. (Amended) The vector of claim 20, wherein the vector is a plasmid, cosmid, yeast artificial chromosome (YAC), BAC artificial chromosome, adenovirus, adeno-associated virus, retrovirus, P1 bacteriophage or eukaryotic viral DNA.

d8

23. (Amended) The adenovirus vector of claim 22, wherein the adenovirus vector comprises an adenovirus genome wherein the p-Hyde gene is inserted within a deletion in the E1 and E3 region of the genome.

54. (Amended) The isolated nucleic acid molecule of claim 1 having at least 75% complementary to the nucleic acid sequence of SEQ ID NO: 1.

d9

55. (Amended) The isolated nucleic acid molecule of claim 1 having at least 85% complementary to the nucleic acid sequence of SEQ ID NO: 1.

56. (Amended) The isolated nucleic acid molecule of claim 1 having at least 95% complementary to the nucleic acid sequence of SEQ ID NO: 1.

57. (Amended) The isolated nucleic acid molecule of claim 1 as set forth in SEQ ID NO: 1.

d10

59. (Amended) The isolated nucleic acid molecule of claim 53, wherein the nucleic acid is cDNA or genomic DNA.

60. (Amended) The isolated nucleic acid molecule of claim 1 encoding an amino acid sequence having the sequence as set forth in SEQ ID NO: 2.

REMARKS

Claims 1, 7, 10-27, 54-57, 59 and 60 are pending in the application. Claims 1, 7, 10-27, 54-57, 59 and 60 have been rejected. Claims 1, 7, 10-12, 17-21, 23, 54-57, 59 and 60 have been amended. The amendments to the claims, specification and abstract contain no new matter. Therefore, Applicants respectfully request entry of the Amendment.